Business · Companies · 54 mins ago
Brazilian hospitals report strong results as health insurers show mixed performance
Brazilian hospitals reported strong third-quarter results, while health insurers had mixed performance.
The results cover the third quarter of 2026 and include companies such as Mater Dei, Rede D’Or, Hapvida and SulAmérica.
Insurers’ revenue growth slowed as average prices rose more slowly, although Hapvida’s average price growth improved.
Hospitals benefited from higher average prices and better margins, despite weaker patient volumes.
Mater Dei led the hospital results, with gross revenue up 16% year over year, compared with 13% in the previous quarter.
Morgan Stanley raised its 2026 pharmaceutical sales forecast to about R$14.3 billion, citing ongoing medicine demand and growth in GLP-1 drugs.
The bank named Hypera its top sector pick, while also viewing RD Saúde positively and describing Pague Menos as higher-risk.
Brazilian health insurers had mixed results in the third quarter of 2026, while hospitals reported positive results.
Bradesco BBI cited slower revenue growth among health plans, driven by more moderate growth in average premiums.
Mater Dei led hospital results, with gross revenue up 16% year on year.
Revenue growth at Rede D’Or and Rede Américas was stable, but average patient-day trends differed.
Morgan Stanley raised its 2026 Brazilian pharmaceutical-sector sales projection to about R$14.3 billion.
- Who
- Brazilian health insurers and hospital operators reported results; Morgan Stanley assessed the pharmaceutical sector.
- What
- Insurers had mixed performance, while hospitals reported positive results.
- When
- In the third quarter of 2026.
- Where
- Brazil.
- Why
- Insurer revenue growth slowed as average-premium growth moderated; hospital revenue growth was supported by higher average prices and margin gains.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Mater Dei revenue
- Gross revenue rose 16% year on year in the third quarter of 2026.
- Mater Dei average ticket
- Rose 14% year on year, compared with 12% in the second quarter.
- BradSaúde average ticket
- Rose 2% year on year, down from 4% in the second quarter.
- SulAmérica average ticket
- Fell 1%, compared with a 2% rise in the previous quarter.
- Pharmaceutical sales projection
- Raised to about R$14.3 billion for 2026.